Assessment of treatment efficacy in HBV infection and disease.

[1]  F. Zoulim,et al.  A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus , 2004, Hepatology.

[2]  J. Molina,et al.  Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[4]  E. Keeffe,et al.  Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.

[5]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[6]  D. Cooper,et al.  Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. , 2004, The Journal of infectious diseases.

[7]  Y. Benhamou.  Antiretroviral therapy and HIV/hepatitis B virus coinfection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Huiling Yang,et al.  In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. , 2004, Antiviral research.

[9]  V. Soriano,et al.  Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Bertoletti,et al.  Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. , 2003, The Journal of infectious diseases.

[11]  F. Rousseau,et al.  Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.

[12]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[14]  R. Tubiana,et al.  Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. , 2003, The New England journal of medicine.

[15]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[16]  P. Marcellin,et al.  Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. , 2002, Gastroenterology.

[17]  Fabien Zoulim,et al.  Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay , 2002, Journal of Clinical Microbiology.

[18]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[19]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[20]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study , 2001, The Lancet.

[21]  L. Stuyver,et al.  Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B , 2000, Hepatology.

[22]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[23]  D. Cooper,et al.  Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. , 1999, The Journal of infectious diseases.

[24]  R. Tubiana,et al.  Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men , 1996, Annals of Internal Medicine.

[25]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.